In a 45-year-old woman using combined oral contraceptive pills (levonorgestrel/ethinyl estradiol), is her overall cancer risk increased and how should cancer screening be performed?

Cancer Risk with Combined Oral Contraceptives in a 45-Year-Old Woman

For a 45-year-old woman taking levonorgestrel/ethinyl estradiol pills, there is a small increased risk of breast cancer during current use (relative risk ~1.24), but this is balanced by reduced risks of endometrial, ovarian, and colorectal cancers that persist for decades after discontinuation. 1, 2

Overall Cancer Risk Profile

The evidence shows that combined oral contraceptives (COCs) do not increase overall lifetime cancer risk or cancer mortality 3, 4. While specific cancer risks vary by type, the protective effects against some cancers counterbalance the increased risks of others:

Increased Risks:

• Breast cancer: Small increased risk during current/recent use (RR 1.08-1.24), which disappears within 5-10 years after discontinuation 1, 2. Notably, levonorgestrel-containing formulations show lower risk compared to other progestins like desogestrel or drospirenone 5
• Cervical cancer: Increased risk with ≥5 years of use, but risk disappears 10 years after discontinuation 1

Decreased Risks (Long-lasting Protection):

• Endometrial cancer: Significantly reduced risk that persists for at least 30 years after stopping 6, 3
• Ovarian cancer: Reduced risk persisting decades after discontinuation 6, 3
• Colorectal cancer: Reduced risk that continues long-term 6, 3

Age-Specific Considerations at 45 Years

At age 45, this patient is approaching the upper age limit where COC benefits typically outweigh risks in healthy, non-smoking women 2. The FDA drug label specifically notes that cardiovascular risks may increase after age 40, but benefits may still outweigh risks in healthy non-smokers 2. She should continue contraception until menopause (median age 51) or age 50-55 years 7.

Cancer Screening Recommendations

Follow standard age-appropriate cancer screening guidelines—COC use does not require additional or modified screening protocols:

Breast Cancer Screening:

• Ages 45-54: Annual mammography 8
• Continue as long as overall health is good and life expectancy ≥10 years 8
• Clinical breast examination as part of routine care
• No additional screening is needed solely due to COC use

Cervical Cancer Screening:

• Continue routine cervical cytology (Pap smear) and/or HPV testing per standard guidelines
• Typically every 3 years with cytology alone (ages 21-65) or every 5 years with co-testing (ages 30-65)
• COC use may warrant discussion about HPV vaccination status if not previously vaccinated

Colorectal Cancer Screening:

• Begin at age 45 per current guidelines (not specifically related to COC use, but age-appropriate)

Endometrial/Ovarian Cancer:

• No routine screening recommended for average-risk women
• Maintain awareness of symptoms (abnormal bleeding, pelvic pain, bloating)

Important Clinical Caveats

Key risk factors that would change recommendations:

• Smoking: Dramatically increases cardiovascular risk, particularly stroke and MI; COCs are relatively contraindicated in smokers >35 years 1, 2
• Personal history of breast cancer: Absolute contraindication to COC use 9, 2, 4
• Strong family history of breast cancer: Consider genetic counseling but does not automatically preclude COC use 1
• Cardiovascular risk factors: Hypertension, diabetes, obesity increase thrombotic risks 1, 2

The absolute increase in breast cancer risk is small (approximately 1 additional case per 7,752 users) 5, and this must be weighed against the substantial protective effects for other cancers and the risks of unintended pregnancy at this age, which carries higher maternal morbidity and mortality than in younger women 7, 2.